HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wang, J. S. Articles by Karp, R. B. Search for Related Content PubMed PubMed Citation Articles by Wang, J. S. Articles by Karp, R. B.

The Journal of Thoracic and Cardiovascular Surgery, Vol 104, 1135-1140, Copyright © 1992 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association

ARTICLES

In vitro effects of aprotinin on activated clotting time measured with different activators

JS Wang, CY Lin, WT Hung, RA Thisted and RB Karp
Department of Anesthesia and Critical Care, University of Chicago Hospitals, Ill. 60637.

The effects in vitro of aprotinin on the activated clotting time measured with both celite- and kaolin-activated tubes were investigated in 21 consecutive patients requiring cardiopulmonary bypass. Four whole- blood samples (2 ml per sample) from each patient were tested simultaneously with Hemochron automated timing systems (International Technidyne Corp., Edison, N.J.) before, during, and after cardiopulmonary bypass. One tenth milliliter of either aprotinin (at a final concentration of 80, 120, or 180 KIU/ml) or saline solution was mixed in vitro with blood samples before determination of the activated clotting time. Aprotinin had no inhibitory effect on the activated clotting times of unheparinized blood. After heparin administration, aprotinin in the above concentrations prolonged the activated clotting times measured with celite-activated tubes by 47% to 71%, as compared with the measurements of the activated clotting time without the addition of aprotinin. The activated clotting times in kaolin-activated tubes were not increased, however, by the in vitro addition of aprotinin. Our in vitro results indicate that aprotinin in concentrations from 80 to 180 KIU/ml does not significantly enhance the inhibitory effects of heparin on the intrinsic coagulation system as evaluated by measurement of the activated clotting times in kaolin- activated tubes. The anticoagulation effect of heparin in patients receiving aprotinin infusion should be monitored with kaolin-activated instead of celite-activated tubes because the celite makes the measured activated clotting time unreliable in patients receiving aprotinin therapy. These in vitro results require confirmation in vivo in patients receiving aprotinin therapy.

This article has been cited by other articles:

				G. Veres, T. Radovits, H. Schultz, L.-n. Lin, J. Hutter, E. Weigang, Z. Szabolcs, and G. Szabo Effect of recombinant aprotinin on postoperative blood loss and coronary vascular function in a canine model of cardiopulmonary bypass Eur. J. Cardiothorac. Surg., August 1, 2007; 32(2): 340 - 345. [Abstract] [Full Text] [PDF]

				A. B. Lerner Aprotinin's Effect on ACT is Not an Artifact Anesth. Analg., May 1, 2007; 104(5): 1302 - 1302. [Full Text] [PDF]

				S. Bar-Yosef, H. B. Cozart, B. Phillips-Bute, J. P. Mathew, and H. P. Grocott Preoperative low molecular weight heparin reduces heparin responsiveness during cardiac surgery: [L'heparine de bas poids moleculaire en preoperatoire reduit la reponse a l'heparine pendant la chirurgie cardiaque] Can J Anesth, February 1, 2007; 54(2): 107 - 113. [Abstract] [Full Text] [PDF]

				A. Vincentelli, B. Jude, and S. Belisle Antithrombotic therapy in cardiac surgery: [Traitement antithrombotique en chirurgie cardiaque]. Can J Anesth, June 1, 2006; 53(6_suppl): S89 - S102. [Abstract] [Full Text] [PDF]

				S. A Spinler, A. K Wittkowsky, E. A Nutescu, and M. A Smythe Anticoagulation Monitoring Part 2: Unfractionated Heparin and Low-Molecular-Weight Heparin Ann. Pharmacother., July 1, 2005; 39(7): 1275 - 1285. [Abstract] [Full Text] [PDF]

				M. A. Smythe and A. Caffee Anticoagulation Monitoring Journal of Pharmacy Practice, October 1, 2004; 17(5): 317 - 326. [Abstract] [PDF]

				J.F. M. Bechtel, J. Prosch, H.-H. Sievers, and C. Bartels Is the kaolin or celite activated clotting time affected by tranexamic acid? Ann. Thorac. Surg., August 1, 2002; 74(2): 390 - 393. [Abstract] [Full Text] [PDF]

				D. Royston, R. Cardigan, C. Gippner-Steppert, and M. Jochum Is Perioperative Plasma Aprotinin Concentration More Predictable and Constant After a Weight-Related Dose Regimen? Anesth. Analg., April 1, 2001; 92(4): 830 - 836. [Abstract] [Full Text] [PDF]

				L. Shore-Lesserson, H. E. Manspeizer, M. Bolastig, D. Harrington, F. Vela-Cantos, and M. DePerio Anticoagulation for Cardiac Surgery in Patients Receiving Preoperative Heparin: Use of the High-Dose Thrombin Time Anesth. Analg., April 1, 2000; 90(4): 813 - 818. [Abstract] [Full Text] [PDF]

				C. R. Smith and T. B. Spanier Aprotinin in deep hypothermic circulatory arrest Ann. Thorac. Surg., July 1, 1999; 68(1): 278 - 286. [Abstract] [Full Text] [PDF]

				R. Pifarre Use of Aprotinin in the Control of Bleeding During Cardiopulmonary Bypass Surgery: Current Status Clinical and Applied Thrombosis/Hemostasis, January 1, 1998; 4(1): 2 - 6. [Abstract] [PDF]

				G. J. Despotis, A. L. Alsoufiev, E. Spitznagel, L. T. Goodnough, and D. G. Lappas Response of Kaolin ACT to Heparin: Evaluation With an Automated Assay and Higher Heparin Doses Ann. Thorac. Surg., March 1, 1996; 61(3): 795 - 799. [Abstract] [Full Text]

				J. H. Levy, R. Pifarre, H. V. Schaff, J. C. Horrow, R. Albus, B. Spiess, T. K. Rosengart, J. Murray, R. E. Clark, P. Smith, et al. A Multicenter, Double-Blind, Placebo-Controlled Trial of Aprotinin for Reducing Blood Loss and the Requirement for Donor-Blood Transfusion in Patients Undergoing Repeat Coronary Artery Bypass Grafting Circulation, October 15, 1995; 92(8): 2236 - 2244. [Abstract] [Full Text]

				G. J. Despotis, J. H. Joist, D. Joiner-Maier, A. L. Alsoufiev, A. N. Triantafillou, L. T. Goodnough, S. A. Santoro, and D. G. Lappas Effect of Aprotinin on Activated Clotting Time, Whole Blood and Plasma Heparin Measurements Ann. Thorac. Surg., January 1, 1995; 59(1): 106 - 111. [Abstract] [Full Text]

				J. H. Lemmer Jr., W. Stanford, S. L. Bonney, J. F. Breen, E. V. Chomka, W. J. Eldredge, W. W. Holt, R. B. Karp, G. W. Laub, M. J. Lipton, et al. Aprotinin for coronary bypass operations: Efficacy, safety, and influence on early saphenous vein graft patencyA multicenter, randomized, double-blind, placebo-controlled study J. Thorac. Cardiovasc. Surg., February 1, 1994; 107(2): 543 - 553. [Abstract] [Full Text]